| 000 | 01870 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517041527.0 | ||
| 264 | 0 | _c20160412 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1742-4658 | ||
| 024 | 7 |
_a10.1111/febs.13367 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDorresteijn, Bram | |
| 245 | 0 | 0 |
_aCamelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo. _h[electronic resource] |
| 260 |
_bThe FEBS journal _cSep 2015 |
||
| 300 |
_a3618-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xgenetics |
| 650 | 0 | 4 |
_aAmyloid Precursor Protein Secretases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aAmyloid beta-Protein Precursor _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAspartic Acid Endopeptidases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCamelids, New World _ximmunology |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fragments _xadministration & dosage |
| 650 | 0 | 4 |
_aImmunoglobulin Heavy Chains _xadministration & dosage |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aRecombinant Proteins _xgenetics |
| 650 | 0 | 4 | _aVaccination |
| 700 | 1 | _aRotman, Maarten | |
| 700 | 1 | _aFaber, Dorien | |
| 700 | 1 | _aSchravesande, Ruud | |
| 700 | 1 | _aSuidgeest, Ernst | |
| 700 | 1 | _avan der Weerd, Louise | |
| 700 | 1 | _avan der Maarel, Silvère M | |
| 700 | 1 | _aVerrips, Cornelis T | |
| 700 | 1 | _aEl Khattabi, Mohamed | |
| 773 | 0 |
_tThe FEBS journal _gvol. 282 _gno. 18 _gp. 3618-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/febs.13367 _zAvailable from publisher's website |
| 999 |
_c25048214 _d25048214 |
||